Vion Pharmaceuticals (VION.OB) Announces Results of Oncologic Advisory Committee Meeting
Vion Pharmaceuticals is a young company that has been breaking new ground with their lead oncology therapeutic Onrigin Injection. Today, results were announced of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for the Onrigin Injection was presented for the indication of remission induction treatment for patients 60 years of age or older with de novo poor-risk myeloid leukemia (AML). The question the U.S. Food and Drug Administration asked ODAC was to vote on the question of whether a randomized study defining the efficacy and safety of Onrigin in the population proposed for the indication be completed prior…